Incyte

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Incyte and other ETFs, options, and stocks.

About INCY

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas.

CEO

William J. Meury

CEOWilliam J. Meury

Employees

2,844

Employees2,844

Headquarters

Wilmington, Delaware

HeadquartersWilmington, Delaware

Founded

1991

Founded1991

Employees

2,844

Employees2,844

INCY Key Statistics

Market cap

26.30B

Market cap26.30B

Price-Earnings ratio

16.50

Price-Earnings ratio16.50

Dividend yield

—

Dividend yield—

Average volume

2.01M

Average volume2.01M

High today

$132.58

High today$132.58

Low today

$118.00

Low today$118.00

Open price

$119.08

Open price$119.08

Volume

5.92M

Volume5.92M

52 Week high

$132.60

52 Week high$132.60

52 Week low

$71.00

52 Week low$71.00

Stock Snapshot

As of today, Incyte(INCY) shares are valued at $131.40. The company's market cap stands at 26.3B, with a P/E ratio of 16.50.

During the trading session on 2026-07-29, Incyte(INCY) shares reached a daily high of $132.58 and a low of $118.00. At a current price of $131.40, the stock is +11.4% higher than the low and still -0.9% under the high.

Trading activity shows a volume of 5.92M, compared to an average daily volume of 2.01M.

The stock's 52-week range extends from a low of $71.00 to a high of $132.60.

INCY News

TipRanks 14h

Incyte price target raised to $145 from $123 at Stifel

Stifel analyst Stephen Willey raised the firm’s price target on Incyte (INCY) to $145 from $123 and keeps a Buy rating on the shares. The company reported Q2 re...

Nasdaq 16h

Incyte Q2 Revenue Jumps 38%, Raises FY26 Sales Guidance

(RTTNews) - Incyte Corp. (INCY) on Tuesday reported an increase in second-quarter earnings and revenue, driven by strong growth across its commercial portfolio....

TipRanks 17h

Prelude Therapeutics rallies after Incyte prioritizes JAK2V617F pipeline

Shares of Prelude Therapeutics (PRLD) after moving higher after Incyte (INCY) in its Q2 earnings release that after a review of available data, it has discontin...

Analyst ratings

55%

of 29 ratings

Buy

41.4%

Hold

55.2%

Sell

3.4%

More INCY News

Nasdaq 20h

Incyte Q2 Earnings and Revenues Top Estimates

Incyte (INCY) came out with quarterly earnings of $3.09 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $1.57 per...

Simply Wall St 1d

Incyte In Focus On Trial Results And Vega Deal As Valuation Questions Persist

Advertisement Why Incyte Stock Is Back in Focus Incyte (INCY) is back on investor watchlists after publishing full safety and efficacy results from its Phase...

People also own

Based on the portfolios of people who own INCY. This list is generated using Robinhood data, and it’s not a recommendation.

Credo Technology Group

Lumentum

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.